GETI.B

206.3

-0.34%↓

CAMX

727

+2.11%↑

VITR

137.5

+2.77%↑

AMBEA

127.3

-1.93%↓

ATT

65.7

-2.95%↓

GETI.B

206.3

-0.34%↓

CAMX

727

+2.11%↑

VITR

137.5

+2.77%↑

AMBEA

127.3

-1.93%↓

ATT

65.7

-2.95%↓

GETI.B

206.3

-0.34%↓

CAMX

727

+2.11%↑

VITR

137.5

+2.77%↑

AMBEA

127.3

-1.93%↓

ATT

65.7

-2.95%↓

GETI.B

206.3

-0.34%↓

CAMX

727

+2.11%↑

VITR

137.5

+2.77%↑

AMBEA

127.3

-1.93%↓

ATT

65.7

-2.95%↓

GETI.B

206.3

-0.34%↓

CAMX

727

+2.11%↑

VITR

137.5

+2.77%↑

AMBEA

127.3

-1.93%↓

ATT

65.7

-2.95%↓

Search

Vivesto AB

Chiusa

0

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

Massimo

Metriche Chiave

By Trading Economics

Entrata

-1.2M

-9.5M

EPS

-0.018

Dipendenti

4

Dividendi

By Dow Jones

Utili prossimi

11 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1.1M

129M

Apertura precedente

0

Chiusura precedente

0

Vivesto AB Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 ago 2025, 22:51 UTC

Utili

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 ago 2025, 23:57 UTC

Utili

Trip.com Group 1H Rev $4.01B

27 ago 2025, 23:57 UTC

Utili

Trip.com Group 1H Adj EPS $1.84

27 ago 2025, 23:57 UTC

Utili

Trip.com Group 1H EPS $1.82

27 ago 2025, 23:50 UTC

Discorsi di Mercato

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 ago 2025, 23:39 UTC

Utili

Correction to Nvidia Earnings Article -- WSJ

27 ago 2025, 22:59 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 ago 2025, 22:59 UTC

Discorsi di Mercato

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 ago 2025, 22:58 UTC

Utili

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 ago 2025, 22:57 UTC

Utili

South32 FY Free Cash Flow $192 Million

27 ago 2025, 22:56 UTC

Utili

South32 FY Total Capital Expenditure $1.35 Billion

27 ago 2025, 22:56 UTC

Utili

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 ago 2025, 22:55 UTC

Utili

South32 Net Cash $123 Million at June 30

27 ago 2025, 22:54 UTC

Utili

South32: Focused on Maintaining Strong Operating Momentum

27 ago 2025, 22:53 UTC

Utili

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 ago 2025, 22:53 UTC

Utili

South32 Extends Capital Management Program for 12 Months

27 ago 2025, 22:52 UTC

Utili

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 ago 2025, 22:51 UTC

Utili

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 ago 2025, 22:51 UTC

Utili

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 ago 2025, 22:50 UTC

Utili

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 ago 2025, 22:50 UTC

Utili

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 ago 2025, 22:45 UTC

Utili

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 ago 2025, 22:44 UTC

Utili

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 ago 2025, 22:44 UTC

Utili

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 ago 2025, 22:43 UTC

Utili

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 ago 2025, 22:43 UTC

Utili

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 ago 2025, 22:42 UTC

Utili

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 ago 2025, 22:42 UTC

Utili

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 ago 2025, 22:40 UTC

Utili

Sandfire Resources Net Debt $123 Million at June 30

27 ago 2025, 22:40 UTC

Utili

Sandfire Resources FY Underlying Ebitda $527.7 Million

Confronto tra pari

Modifica del prezzo

Vivesto AB Previsione

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.